Arcus Biosciences Email Format
Biotechnology
・
501-1,000 employees
・
Hayward, CA, USA
Arcus Biosciences is a clinical-stage biopharmaceutical company developing differentiated cancer therapies and combination medicines to address areas of high unmet medical need.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@arcusbio.com
Company Overview
Industry
Biotechnology
Founded
2015
Headquarters
Hayward, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Website
Key Executives
Terry Rosen (Chief Executive Officer), Bob Goeltz (Chief Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Arcus Biosciences?
Arcus Biosciences uses the firstinitiallast format, so Jane Smith would be jsmith@arcusbio.com.
What therapeutic areas does Arcus Biosciences focus on in its clinical pipeline?
Arcus Biosciences runs clinical programs across two main areas: oncology, including kidney and lung cancer, and inflammation and immunology, with candidates targeting atopic dermatitis, rheumatoid arthritis, and multiple sclerosis.
How does casdatifan fit into the Arcus Biosciences oncology strategy?
Casdatifan is Arcus Biosciences' HIF-2 alpha inhibitor in development for clear cell renal cell carcinoma, with ongoing trials spanning post-IO and first-line kidney cancer settings. It is among the company's most advanced oncology assets in 2026.
Who leads Arcus Biosciences and who can I contact for business development inquiries?
Terry Rosen serves as Chief Executive Officer of Arcus Biosciences, with Bob Goeltz as Chief Financial Officer. Business development inquiries can be directed to BD@arcusbio.com, and tools like Clay can help verify or enrich contacts before outreach.
Does Arcus Biosciences have any active partnerships with other pharmaceutical companies?
Arcus Biosciences has active collaborations with Gilead Sciences, Taiho, and AstraZeneca. The AstraZeneca partnership includes the Phase 3 PACIFIC-8 trial evaluating domvanalimab combined with durvalumab in unresectable Stage III non-small cell lung cancer.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating